EcoDrugPlus

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSPNAG00000028555
Gene Symbol: LOC108427087
3 Cross references
195 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSPNAG00000029268
Gene Symbol: NPR2
3 Cross references
191 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSPNAG00000027783
Gene Symbol: NPR2
2 Cross references
184 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSPNAG00000003857
Gene Symbol: NPR3
3 Cross references
212 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1

Ensembl ID : ENSPNAG00000010169
Gene Symbol: LOC108413122
3 Cross references
196 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSPNAG00000016457
Gene Symbol: LOC108429650
3 Cross references
199 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSPNAG00000011051
Gene Symbol: LOC108411976
3 Cross references
243 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSPNAG00000024465
Gene Symbol: LOC108415119
3 Cross references
196 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSPNAG00000020867
Gene Symbol: LOC108434558
3 Cross references
205 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSPNAG00000003354
Gene Symbol: LOC108444230
2 Cross references
183 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSPNAG00000000921
Gene Symbol: NPY2R
3 Cross references
184 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSPNAG00000025345
Gene Symbol: LOC108439369
3 Cross references
178 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).